[Passive immunotherapy in Sars-Cov2 infections].

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• The COVID-19 pandemic necessitated rapid development of therapeutic and prophylactic strategies.
• Antibody-based therapies emerged as a promising avenue for managing SARS-CoV-2 infections.

Purpose of the Study:

• To provide a comprehensive overview of antibody applications in COVID-19.
• To summarize the status of polyclonal and monoclonal antibodies by November 2021.
• To discuss their roles as immunomodulators or direct antiviral agents.

Main Methods:

• Review of scientific literature and clinical trial data up to November 2021.
• Analysis of antibody mechanisms of action in the context of SARS-CoV-2.

Main Results:

• Polyclonal and monoclonal antibodies have been investigated for both preventing and treating COVID-19.
• These antibodies function either by modulating the immune response or by directly neutralizing the SARS-CoV-2 virus.
• The landscape of antibody therapies evolved significantly by November 2021.

Conclusions:

• Antibody therapies represent a key component in the COVID-19 therapeutic armamentarium.
• Continued research is essential to optimize the use and efficacy of these treatments.